Saturday, July 25, 2026

Patent intelligence · WO

WO 2021099616

MASITINIB POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE

granted A61K 31/ 496 A IA61K/31426A61K/31496A61P 7/ 06 A I
Status granted
Linked drugs 1
Years to expiry 15
Applicant portfolio 15
Patent details — WO 2021099616
Jurisdiction
WO
Status
granted
Grant date
May 27, 2021
Expiration
May 22, 2041
Applicant
AB SCIENCE [FR]
CPC classes
A61K 31/ 496 A I, A61K/31426, A61K/31496, A61P 7/ 06 A I
View on Google Patents ↗

Quick answer

WO 2021099616 (MASITINIB POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE) is held by AB SCIENCE [FR]. Status: granted. Granted May 27, 2021. Expires May 22, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
AB SCIENCE [FR]
Grant date
Expiration
Claims
CPC classes
A61K 31/ 496 A I, A61K/31426, A61K/31496, A61P 7/ 06 A I, A61P 11/ 00 A I, A61P/1100

More from AB SCIENCE [FR]

Related pharmaceutical patents in our USPTO index.

  1. CA 3217490

    MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION

    AB SCIENCE [FR] · Expires Nov 19, 2042

    granted
  2. CA 3201259

    MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    AB SCIENCE [FR] · Expires Jun 18, 2042

    granted
  3. CA 3174748

    UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)

    AB SCIENCE [FR] · Expires Oct 9, 2041

    granted
  4. CA 3168610

    MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS SOUFFRANT DE SCLEROSE EN PLAQUES

    AB SCIENCE [FR] · Expires Aug 21, 2041

    granted
  5. EP 3831384

    VERWENDUNG VON MASITINIB ZUR BEHANDLUNG VON EOSINOPHILEM ASTHMA

    AB SCIENCE [FR] · Expires Jun 4, 2041

    granted
  6. CA 3018635

    UTILISATION DE MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS ATTEINTS DE SCLEROSE LATERALE AMYOTROPHIQUE

    AB SCIENCE [FR] · Expires Sep 23, 2037

    granted
  7. WO 2017072335

    UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

    AB SCIENCE [FR] · Expires Apr 29, 2037

    granted

Frequently asked questions

What is US patent 2021099616?

WO 2021099616 (MASITINIB POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE) is held by AB SCIENCE [FR]. Status: granted. Granted May 27, 2021. Expires May 22, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2021099616?

AB SCIENCE [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.

When does WO 2021099616 expire?

Our index shows an expiration date of May 22, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.